These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12005246)

  • 21. Prediction of chronic renal allograft dysfunction from evaluations of TGFBeta1 and the renin-angiotensin system.
    Yamada K; Hatakeyama E; Arita S; Sakamoto K; Kashiwabara H; Hamaguchi K
    Clin Exp Nephrol; 2003 Sep; 7(3):238-42. PubMed ID: 14586721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
    Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy.
    Bönner G; Lederle RM; Scholze J; Stumpe KO
    Arzneimittelforschung; 1993 Aug; 43(8):852-5. PubMed ID: 8216441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats.
    Naelten G; Liu KL; Chapuis B; Lo M
    Am J Hypertens; 2005 May; 18(5 Pt 1):699-706. PubMed ID: 15882554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
    Sebeková K; Lill M; Boor P; Heidland A; Amann K
    Am J Nephrol; 2009; 29(3):164-70. PubMed ID: 18753741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
    Matsuda H; Hayashi K; Homma K; Yoshioka K; Kanda T; Takamatsu I; Tatematsu S; Wakino S; Saruta T
    Hypertens Res; 2003 Nov; 26(11):875-80. PubMed ID: 14714578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the renin-angiotensin system: no effect on circulating macrophage colony-stimulating factor levels in acute myocardial infarction.
    Kurosaki K; Ikeda U; Murakami Y; Takahashi M; Shimada K
    J Cardiovasc Pharmacol; 2003 Jul; 42(1):37-41. PubMed ID: 12827024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S; Liu Y; Wang L; Meng QH
    Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R; Siva S; Dunn SR; Sharma K
    Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition.
    Langham RG; Kelly DJ; Gow RM; Zhang Y; Cordonnier DJ; Pinel N; Zaoui P; Gilbert RE
    Diabetes Care; 2006 Dec; 29(12):2670-5. PubMed ID: 17130203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
    Rossing K; Christensen PK; Hansen BV; Carstensen B; Parving HH
    Diabetes Care; 2003 Jan; 26(1):150-5. PubMed ID: 12502672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients.
    Iñigo P; Campistol JM; Lario S; Piera C; Campos B; Bescós M; Oppenheimer F; Rivera F
    J Am Soc Nephrol; 2001 Apr; 12(4):822-827. PubMed ID: 11274244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased urinary excretion of alpha1-microglobulin at 6 months after transplantation is associated with urinary excretion of transforming growth factor-beta1 and indicates poor long-term renal outcome.
    Teppo AM; Honkanen E; Finne P; Törnroth T; Grönhagen-Riska C
    Transplantation; 2004 Sep; 78(5):719-24. PubMed ID: 15371675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients.
    Sennesael J; Lamote J; Violet I; Tasse S; Verbeelen D
    Hypertension; 1995 Sep; 26(3):436-44. PubMed ID: 7649579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease.
    Lizakowski S; Tylicki L; Renke M; Rutkowski P; Heleniak Z; Sławińska-Morawska M; Aleksandrowicz-Wrona E; Małgorzewicz S; Rutkowski B
    Am J Hypertens; 2012 Jun; 25(6):636-9. PubMed ID: 22357413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of an angiotensin-converting enzyme inhibitor improves vascular function and urinary albumin excretion in low-risk essential hypertensive patients receiving anti-hypertensive treatment with calcium channel blockers. Organ-protecting effects independent of anti-hypertensive effect.
    Watanabe Y; Takasugi E; Shitakura K; Okajima K; Hota N; Kubo Y; Nunoda S; Otsuka K
    Clin Exp Hypertens; 2011; 33(4):246-54. PubMed ID: 21699451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.